3-(3-(6-Benzoyloxy-3-cyano-2-pyridyloxycarbonyl)benzoyl)-3'-O-benzyl-2'-deoxy-5-fluorouridine
CAS : 103767-48-2
Ref. 3D-FB101960
| Taille indéfinie | Arrêté |
Informations sur le produit
- Benzoic acid, 3-((3-(2-deoxy-3-O-(phenylmethyl)-beta-D-erythro-pentofuranosyl)-5-fluoro-3,6-dihydro-2,6-dioxo-1(2H)-pyrimidinyl)carbonyl)-, 6-(benzoyloxy)-3-cyano-2-pyridinyl ester
- 3-[3-({[6-(benzoyloxy)-3-cyanopyridin-2-yl]oxy}carbonyl)benzoyl]-3'-O-benzyl-2'-deoxy-5-fluorouridine
- Bof A1
- Bof-A1
Fluorouracil is a pyrimidine-based chemotherapy drug that inhibits DNA synthesis by inhibiting the activity of the enzyme thymidylate synthase, thereby preventing the production of thymine nucleotides. Fluorouracil is used to treat cancers such as colorectal cancer and breast cancer. It is also used as adjuvant therapy for head and neck cancer. Fluorouracil works by binding to the enzyme dihydrofolate reductase, which is required for the synthesis of DNA precursors. This binding prevents the formation of tetrahydrofolate, which is essential for cell division. The main side effects are myelosuppression and gastrointestinal toxicities, which can be reduced or prevented with appropriate doses (lowering dose) or discontinuation (in case of gastrointestinal toxicity).
